Bard Wins Evidentiary Ruling for First Federal Clot Filter Trial

Jan. 30, 2018, 7:04 PM

C.R. Bard Inc. notched an evidentiary win ahead of the first test trial in federal multidistrict litigation alleging its blood-clot trapping filters harmed more than 3,000 recipients.

The company may present evidence that the Food and Drug Administration authorized the IVC filters for sale based on equivalence to a device on the market, the U.S. District Court for the District of Arizona said Jan. 29.

Trial is set to start March 14.

The court didn’t follow the approach taken by the court overseeing federal pelvic mesh litigation, in which Bard, Johnson & Johnson and others weren’t allowed to tell juries ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.